Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
View original at globenewswire.comMesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive w…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast's products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration
60% confidenceRyoncil is the first FDA-approved mesenchymal stromal cell (MSC) therapy
60% confidenceThis provides Mesoblast with an immediate opportunity to generate products with even greater potency for ulcerative colitis or Crohn's disease
60% confidenceMayo Clinic has a financial interest in the technology through a license agreement with Mesoblast and will use any revenue to support its not-for-profit mission in patient care, education and research
60% confidenceMesoblast plans to use CAR-MSC engineered to express CD19 on their surface to induce remission in Lupus Nephritis and other B cell autoimmune diseases where durable, effective and safe immunomodulation is highly desirable
60% confidenceThis innovative genetic modification technology fits well with our strategy to extend our market leadership by creating products with even greater efficacy and new target indications
60% confidenceThe aim of genetically engineering CAR constructs into MSCs is to substantially enhance targeted homing to inflamed tissue resulting in greater potency
60% confidence